Home
News Intelligence
Oryzon Genomics S.A.

Oryzon Genomics S.A.

Healthcare · Biotechnology

BME:ORY
OTC PINK:ORYZF

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

Latest announcement

Regulatory approval

Sep 28, 2026

Oryzon receives EMA authorisation to initiate HOPE-2 Phase IIa study in PMS

Oryzon Genomics has received European Medicines Agency authorisation to initiate HOPE-2, a Phase IIa study evaluating vafidemstat in adults with Phelan-McDermid Syndrome.

View summary and FAQs

Announcement Summary
Investor FAQs
Video
Interactive Chat

Latest by type

Financial results: Oryzon reports first-half 2026 results alongside clinical and financing updates Jul 27, 2026
Financing: Oryzon completes €12 million capital increase and signs conditional COFIDES subscription agreement Jul 01, 2026
Operational update: Oryzon Reports Updated Iadademstat Data from AML Trials at EHA 2026 Jun 11, 2026
Management change: Oryzon appoints Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS programmes Feb 12, 2026

Announcements

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

About, from recent announcements

Oryzon Genomics S.A. is a clinical-stage biopharmaceutical company evaluating vafidemstat in CNS disorders and iadademstat in oncology and haematology. It announced that the European Medicines Agency had authorised the Clinical Trial Application for the HOPE-2 Phase IIa study of vafidemstat in adults with Phelan-McDermid Syndrome. It also announced a U.S. Notice of Allowance for a patent application covering combinations of iadademstat with gilteritinib for treating myeloid cancers, including acute myeloid leukaemia, and reported financial results and a corporate update.

Sources: 3 announcements

Oryzon Genomics S.A.

Get alerts

Oryzon receives EMA authorisation to initiate HOPE-2 Phase IIa study in PMS

Latest by type

Announcements

Oryzon reports U.S. Notice of Allowance for iadademstat-gilteritinib patent application

Oryzon reports first-half 2026 results alongside clinical and financing updates

Oryzon reports U.S. patent grant covering vafidemstat in non-aggressive BPD symptoms

Oryzon completes €12 million capital increase and signs conditional COFIDES subscription agreement

Oryzon Reports Updated Iadademstat Data from AML Trials at EHA 2026